机构名称：
¥ 3.0
Individual has a personal history of a Primary Solid Tumor (excluding basal or squamous cell skin cancer) and at least one of the following: o A pathogenic variant was detected in tumor tissue that has clinical implications if detected in the germline (e.g., BRCA1, BRCA2, BRIP1, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, RAD51C, RAD51D, RET, SDHAF2, SDHB, SDHC, SDHD, TMEM127, TSC2, VHL APC, PTEN, RB1, and TP53 ) o Tumor tissue testing demonstrated that the cancer was MSI-high or had immunohistochemical staining showing the absence of one or more mismatch repair (MMR) proteins ( MLH1, MSH2, MSH6, or PMS2 ) o Individual has a Tyrer-Cuzick, BRCAPro, or Penn11 Score of 2.5% or greater for a BRCA1/2 pathogenic variant o Individual has a PREMM 5 , MMRpro, or MMRpredict Score of 2.5% or greater for having a Lynch syndrome gene mutation Individuals With No Personal History of a Primary Solid Tumor Genetic testing with a Multi-Gene hereditary cancer Panel or testing of BRCA1/2 for individuals如果符合以下至少一个标准之一，则没有原发性实体瘤的个人病史（不包括基底或鳞状细胞皮肤癌），并且在医学上是必不可少的：
遗传癌的基因检测
主要关键词
相关文件推荐
